参考文献/References:
［1］Berek JS，Howe C，Lagasse LD，et al．Pelvic exenteration for recurrent gynecologic malignancy：survival and morbidity analysis “the 45-year experience at UCLA” ［J］．Gynecol Oncol，2005,99（1）:153-159．
［2］李雷，吴鸣，马水清，等．盆腔廓清术治疗妇科恶性肿瘤40例研究 ［J］．中国实用妇科与产科杂志，2016，32（10）：967-972．
［3］刘继红，黄鹤，万挺．盆腔器官廓清术在复发宫颈癌治疗中的价值 ［J］．中国实用妇科与产科杂志，2018，34（11）：1223-1226．
［4］Stanhope CR, Symmonds RE. Palliative exenteration: what, when, and why? ［J］. Am J Obstet Gynecol 1985，152（1）:12-16.
［5］PATHIRAJA P, TOZZI R. Advances in gynaecological oncology surgery ［J］. Best Practice & Research Clinical Obstetrics & Gynaecology, 2013, 27(3): 415-420.
［6］ELIT L, FYLES A W, DEVRIES M C, et al. Follow-up for women after treatment for cervical cancer: a systematic review ［J］. Gynecologic Oncology, 2009, 114(3): 528-535.
［7］陈圆，王志启，邓浩，等．复发性子宫颈癌行盆腔廓清术围术期情况及近期预后分析［J］．实用妇产科杂志，2019，35（2）：141-145．
［8］Barakat R, Goldman A, Patel A, et al.Pelvic exenteration for recurrent endometrial cancer ［J］.Gynecol Oncol, 1999, 75(1):99-102.
［9］SCHMIDT A M, IMESCH P, FINK D, et al. Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients ［J］. International Journal of Gynecological Cancer, 2016, 26(4): 716-721.
［10］BERRETTA R, MARCHESI F, VOLPI L, et al. Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer:clinical and functional outcome［J］. International Journal of Gynecological Cancer,2016,55(3):346-350.
［11］BERRETTA R, CAPOZZI V A, SOZZI G, et al. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer ［J］. Archives of Gynecology and Obstetrics, 2018, 297(4): 997-1004.
［12］Rotmensch J, Rubin SJ, Sutton HG, et al. Preoperative radiotherapy followed by radical vulvectomy with inguinal lymphadenectomy for advanced vulvar carcinomas ［J］. Gynecol Oncol,1990,36(2):181-184.
［13］Hoffman S, Cavanagh D, Roberts S, et al. Ultraradical surgery for advanced carcinoma of the vulva:an update ［J］. Int J Gynecol Cancer, 1993, 3(6):369-372.
［14］胡君，陶霞．盆腔脏器廓清术在妇科恶性肿瘤中的应用进展 ［J］．中国妇产科临床杂志，2014，15（4）：375-378．
［15］JURADO M, LUIS ALCAZAR J, MARTINEZ-MONGE R. Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: Is still the clinical involvement of the pelvis wall a real contraindication? A twenty-year experience ［J］. Gynecologic Oncology, 2010, 116(1): 38-43.
［16］Tanaka S，Nagase S，Kaiho—Sakuma M，et al．Clinical outcome of pelvic exenteration in 282 patients with advanced or recurrent uterine cervical cancer ［J］．Int J Clin Oncol，2014,19(1):133-138．
［17］HCKEL M, HORN L C, EINENKEL J. Laterally extended endopelvic resection:surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy ［J］. Gynecologic Oncology, 2012, 127(2): 297-302.
［18］LEI Li, MA Shui-qing, TAN Xian-jie, et al. Pelvic exenteration for recurrent and persistent cervical cancer ［J］. Chinese Medical Journal, 2018, 131(13): 1541-1548.
［19］WEIMANN A, BRAGA M, CARLI F, et al. ESPEN guideline: Clinical nutrition in surgery ［J］. Clinical Nutrition (Edinburgh, Scotland), 2017, 36(3): 623-650.
［20］石汉平．营养治疗的疗效评价 ［J］．肿瘤代谢与营养电子杂志，2017，4（4）：364-370．
［21］KITAJIMA K, MURAKAMI K, YAMASAKI E, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT ［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36(3): 362-372.
［22］CHUNG H H, KIM S K, KIM T H, et al. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer:from diagnosis to prognosis ［J］. Gynecologic Oncology, 2006, 103(1): 165-170.
［23］Schmidt AM, Imesch P, Fink D,et al. Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer ［J］. Gynecol Oncol,2012;125(3):604-609.
［24］BEIDERWELLEN K, GRUENEISEN J, RUHLMANN V, et al. FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis:initial results ［J］.Eur J Nucl Med Mol Imaging, 2015, 42(1): 56-65.
［25］SAGEBIEL T L, VISWANATHAN C, PATNANA M A, et al. Overview of the role of imaging in pelvic exenteration ［J］. Radio Graphics, 2015, 35(4): 1286-1294.
［26］ALEMOZAFFAR M, NAM C S, SAID M A, et al. Avoiding the need for bowel anastomosis during pelvic exenteration-urinary sigmoid or descending colon Conduit-Short and long term complications ［J］. Urology, 2019, 129(3): 228-233.
［27］MATSUO K, MANDELBAUM R S, ADAMS C L, et al. Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study ［J］. Gynecologic Oncology, 2019, 153(2): 368-375.
［28］CLARK D G, BRUNSCHWIG A, DANIEL W W. Intestinal fistulas following pelvic exenteration ［J］. American Journal of Obstetrics and Gynecology, 1962, 84(2): 187-191.
［29］CHESSIN D B, HARTLEY J, COHEN A M, et al. Rectus flap Reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study ［J］. Annals of Surgical Oncology, 2005, 12(2): 104-110.
［30］Boris, Schiltz, Nicolas, et al. Biological mesh Reconstruction of the pelvic floor following abdominoperineal excision for cancer:A review ［J］. World Journal of Clinical Oncology, 2017, 8(3): 249-254.
［31］POMEL C, ROUZIER R, POCARD M, et al. Laparoscopic total pelvic exenteration for cervical cancer relapse ［J］. Gynecologic Oncology, 2003, 91(3): 616-618.
［32］LIM P C. Robotic assisted total pelvic exenteration: A case report ［J］. Gynecologic Oncology, 2009, 115(2): 310-311.
［33］IAVAZZO C, GKEGKES I D. Robotic technology for pelvic exenteration in cases of cervical cancer ［J］. International Journal of Gynecology & Obstetrics, 2014, 125(1): 15-17.
［34］YANG Qi-yu, TANG Jun-ying. Application of robot-assisted laparoscopic pelvic exenteration in treating gynecologic malignancies ［J］. Chinese Medical Journal, 2019, 132(8): 976-979.
［35］Bizzarri Nicolò, Chiantera Vito, Ercoli Alfredo,et al. Minimally Invasive Pelvic Exenteration for Gynecologic Malignancies: A Multi-Institutional Case Series and Review of the Literature ［J］. Journal of minimally invasive gynecology,2019,26(1):s1553-4650.
［36］THIGPEN T, SHINGLETON H, HOMESLEY H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix:a phase II study of the Gynecologic Oncology Group ［J］. Cancer, 1981, 48(4): 899-903.
［37］陈圆，王志启，王建六．子宫颈癌放疗后盆腔复发手术治疗4例临床分析 ［J］．中国妇产科临床杂志，2018，19（2）：155-156．
［38］张翔，俞华．复发宫颈癌再次放疗 ［J］．国际肿瘤学杂志，2015，42（2）：153-156．
［39］GUREN M G, UNDSETH C, REKSTAD B L, et al. Reirradiation of locally recurrent rectal cancer: A systematic review ［J］. Radiotherapy and Oncology, 2014, 113(2): 151-157.
［40］GEMIGNANI M L, ALEKTIAR K M, LEITAO M, et al. Radical surgical resection and high-dose intraoperative radiation therapy(HDR-IORT)in patients with recurrent gynecologic cancers ［J］. International Journal of Radiation Oncology, Biology, Physics, 2001, 50(3): 687-694.
［41］KNIGHT S, LAMBAUDIE E, SABIANI L, et al. Pelvic exenterations for gynecologic cancers: A retrospective analysis it of a 30-year experience in a cancer center ［J］. EJSO, 2018, 44(12): 1929-1934.
［42］PEIRETTI M, ZAPARDIEL I, ZANAGNOLO V, et al. Management of recurrent cervical cancer: a review of the literature ［J］. Surgical Oncology, 2012, 21(2): e 59-e 66.
［43］MARNITZ S, KOEHLER C, MUELLER M A, et al. Indications for primary and secondary exenterations in patients with cervical cancer ［J］. Gynecologic Oncology, 2006, 103(3): 1023-1030.
［44］Baiocchi G, Guimaraes GC, Faloppa CC, et al. Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer? ［J］.Ann SurgOncol，2013,20(5):1694–1700.
［45］MOUTARDIER V, HOUVENAEGHEL G, MARTINO M, et al. Surgical resection of locally recurrent cervical cancer: a single institutional 70 patient series ［J］. International Journal of Gynecological Cancer, 2004, 14(5): 846-851.
［46］BENN T, BROOKS R A, ZHANG Q, et al. Pelvic exenteration in gynecologic oncology: A single institution study over 20 years ［J］. Gynecologic Oncology, 2011, 122(1): 14-18.
［47］LANDONI F, ZANAGNOLO V, ROSENBERG P G, et al. Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer:single institution experience ［J］. Gynecologic Oncology, 2013(130): 69-74.
［48］BHANGU A, ALI S M, DARZI A, et al. Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer ［J］. Colorectal Disease, 2012, 14(12): 1457-1466.
［49］YOUNG J M, BADGERY-PARKER T, MASYA L M, et al. Quality of life and other patient-reported outcomes following exenteration for pelvic malignancy ［J］. British Journal of Surgery, 2014, 101(3): 277-287.